{"id":"https://openalex.org/W4281664559","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e19016","title":"Comparison of different treatment modalities for favorable risk acute myeloid leukemia: Standard-dose anthracycline versus high-dose anthracycline versus addition of gemtuzumab ozogamicin.","display_name":"Comparison of different treatment modalities for favorable risk acute myeloid leukemia: Standard-dose anthracycline versus high-dose anthracycline versus addition of gemtuzumab ozogamicin.","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4281664559","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e19016"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.e19016","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e19016","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.e19016","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037523709","display_name":"Joseph F. Mort","orcid":"https://orcid.org/0000-0002-5168-4030","observed_orcids":["https://orcid.org/0000-0002-5168-4030"]},"institutions":[{"id":"https://openalex.org/I2799765794","display_name":"University of Virginia Health System","ror":"https://ror.org/00wn7d965","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799765794"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Mort","raw_affiliation_strings":["University of Virginia Health System, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia Health System, Charlottesville, VA;","institution_ids":["https://openalex.org/I2799765794"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011672059","display_name":"Leah Wells","orcid":"https://orcid.org/0000-0001-7820-5397","observed_orcids":["https://orcid.org/0000-0001-7820-5397"]},"institutions":[{"id":"https://openalex.org/I51556381","display_name":"University of Virginia","ror":"https://ror.org/0153tk833","country_code":"US","type":"education","lineage":["https://openalex.org/I51556381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leah Wells","raw_affiliation_strings":["University of Virginia, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia, Charlottesville, VA;","institution_ids":["https://openalex.org/I51556381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090482207","display_name":"Samantha DiBenedetto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I51556381","display_name":"University of Virginia","ror":"https://ror.org/0153tk833","country_code":"US","type":"education","lineage":["https://openalex.org/I51556381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samantha DiBenedetto","raw_affiliation_strings":["University of Virginia, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia, Charlottesville, VA;","institution_ids":["https://openalex.org/I51556381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006883090","display_name":"Emily Morse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799765794","display_name":"University of Virginia Health System","ror":"https://ror.org/00wn7d965","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799765794"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily Morse","raw_affiliation_strings":["University of Virginia Health System, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia Health System, Charlottesville, VA;","institution_ids":["https://openalex.org/I2799765794"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004563725","display_name":"Benjamin Mautner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799765794","display_name":"University of Virginia Health System","ror":"https://ror.org/00wn7d965","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799765794"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ben Mautner","raw_affiliation_strings":["University of Virginia Health System, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia Health System, Charlottesville, VA;","institution_ids":["https://openalex.org/I2799765794"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021250966","display_name":"Farid Ghamsari","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I51556381","display_name":"University of Virginia","ror":"https://ror.org/0153tk833","country_code":"US","type":"education","lineage":["https://openalex.org/I51556381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farid Ghamsari","raw_affiliation_strings":["University of Virginia School of Medicine, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia School of Medicine, Charlottesville, VA;","institution_ids":["https://openalex.org/I51556381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061496450","display_name":"Eric J Pierce","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I51556381","display_name":"University of Virginia","ror":"https://ror.org/0153tk833","country_code":"US","type":"education","lineage":["https://openalex.org/I51556381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Pierce","raw_affiliation_strings":["University of Virginia, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia, Charlottesville, VA;","institution_ids":["https://openalex.org/I51556381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111954556","display_name":"Amy Morris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I51556381","display_name":"University of Virginia","ror":"https://ror.org/0153tk833","country_code":"US","type":"education","lineage":["https://openalex.org/I51556381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Morris","raw_affiliation_strings":["University of Virginia, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia, Charlottesville, VA;","institution_ids":["https://openalex.org/I51556381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072077108","display_name":"Michael Kenneth Keng","orcid":"https://orcid.org/0000-0002-7679-6514","observed_orcids":["https://orcid.org/0000-0002-7679-6514"]},"institutions":[{"id":"https://openalex.org/I2799765794","display_name":"University of Virginia Health System","ror":"https://ror.org/00wn7d965","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799765794"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Kenneth Keng","raw_affiliation_strings":["University of Virginia Health System, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia Health System, Charlottesville, VA;","institution_ids":["https://openalex.org/I2799765794"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050393257","display_name":"Firas El Chaer","orcid":"https://orcid.org/0000-0001-9596-0714","observed_orcids":["https://orcid.org/0000-0001-9596-0714"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Firas El Chaer","raw_affiliation_strings":["UVA Health System, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UVA Health System, Charlottesville, VA;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"e19016","last_page":"e19016"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anthracycline-dose","display_name":"anthracycline dose","score":0.7630000114440918},{"id":"https://openalex.org/keywords/daunorubicin","display_name":"daunorubicin","score":0.9480000138282776},{"id":"https://openalex.org/keywords/idarubicin","display_name":"idarubicin","score":1.0},{"id":"https://openalex.org/keywords/gemtuzumab-ozogamicin","display_name":"gemtuzumab ozogamicin","score":0.9929999709129333},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.8320000171661377},{"id":"https://openalex.org/keywords/event-free-survival","display_name":"event-free survival","score":0.9589999914169312},{"id":"https://openalex.org/keywords/relapse-free-survival","display_name":"relapse-free survival","score":0.8679999709129333},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9100000262260437},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.7699999809265137},{"id":"https://openalex.org/keywords/cytopenia","display_name":"cytopenia","score":0.6359999775886536},{"id":"https://openalex.org/keywords/treatment-related-complications","display_name":"treatment complications","score":0.5379999876022339},{"id":"https://openalex.org/keywords/cytogenetic-risk","display_name":"cytogenetic risk","score":0.460999995470047}],"concepts":[{"id":"https://openalex.org/C2778623314","wikidata":"https://www.wikidata.org/wiki/Q412685","display_name":"Gemtuzumab ozogamicin","level":5,"score":0.9469175338745117},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9100799560546875},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.9048988819122314},{"id":"https://openalex.org/C2779117419","wikidata":"https://www.wikidata.org/wiki/Q1063862","display_name":"Idarubicin","level":4,"score":0.8811324834823608},{"id":"https://openalex.org/C2781021840","wikidata":"https://www.wikidata.org/wiki/Q411659","display_name":"Daunorubicin","level":3,"score":0.7457688450813293},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6835752129554749},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.6784417629241943},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5845097303390503},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5285550355911255},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.42241576313972473},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4130253195762634},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.389911949634552},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3678566813468933},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.14126229286193848},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.07381409406661987},{"id":"https://openalex.org/C176290653","wikidata":"https://www.wikidata.org/wiki/Q21114013","display_name":"CD33","level":4,"score":0.06970560550689697},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.e19016","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e19016","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.e19016","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4283316752","https://openalex.org/W4404765593","https://openalex.org/W2988819815","https://openalex.org/W3154383630","https://openalex.org/W2984351169","https://openalex.org/W2588329438","https://openalex.org/W2891369366","https://openalex.org/W4417013032","https://openalex.org/W4405050108","https://openalex.org/W2581188263"],"abstract_inverted_index":{"e19016":[0],"Background:":[1],"The":[2,156,172,232,260,317],"standard":[3,93],"remission":[4,176],"induction":[5,146,239],"regimen":[6],"for":[7,402],"medically":[8,68],"fit":[9,69],"patients":[10,40,70,139,160,333],"with":[11,41,58,74,81,147,350],"AML":[12,77],"consists":[13],"of":[14,17,29,86,112,117,122,132,142,159,174,236,262,319,357,360,385],"a":[15,64,342,351,372],"backbone":[16],"cytarabine":[18],"&":[19,27,35,152,166,181,187,199,211,227,234,323,347,366,393],"an":[20],"anthracycline":[21,31,113],"(\u201c7+3\u201d":[22],"therapy).":[23],"However,":[24],"the":[25,30,84,115,178,255,267,282,355,389],"choice":[26],"dose":[28,94,103],"varies":[32],"between":[33,222],"institutions":[34],"practitioner":[36],"preference,":[37],"particularly":[38],"in":[39,51,177,254,281,288,291,294,299,302,305,309,312,315],"favorable":[42,75],"risk":[43,76],"cytogenetics.":[44],"Gemtuzumab":[45],"ozogamicin":[46],"(GO)":[47],"may":[48],"improve":[49],"outcomes":[50,376],"this":[52],"patient":[53],"population":[54],"but":[55],"is":[56,388,400],"associated":[57],"increased":[59],"toxicities.":[60],"Methods:":[61],"We":[62],"performed":[63],"retrospective":[65],"analysis":[66,399],"on":[67,92],"\u2265":[71],"18":[72],"yo":[73],"from":[78],"2015-2020":[79],"treated":[80],"7+3":[82],"at":[83,194,206,218,354],"University":[85],"Virginia.":[87],"Patients":[88,338,368],"were":[89,140,161,184,240,251,279,327],"stratified":[90],"based":[91],"(45":[95],"or":[96,107],"60":[97,163],"mg/m2":[98,105,109],"daunorubicin)":[99],"(SD)":[100],"vs":[101,114],"higher":[102,280,358],"(90":[104],"daunorubicin":[106],"12":[108],"idarubicin)":[110],"(HD)":[111],"addition":[116],"GO.":[118,155],"Measures":[119],"included":[120],"rates":[121,131,173,261,359],"remission,":[123],"EFS,":[124],"RFS,":[125,348],"and":[126,272],"OS":[127,217,353],"as":[128,130],"well":[129],"treatment-related":[133],"complications.":[134],"Results:":[135],"In":[136],"total,":[137],"58":[138],"identified,":[141],"which":[143],"33":[144],"received":[145,150,154,380],"SD,":[148,179,289,300,310],"19":[149],"HD,":[151,292,303,313],"6":[153],"majority":[157],"(75%)":[158],"<":[162,277],"years":[164],"old":[165],"93%":[167],"had":[168,341,371],"de":[169],"novo":[170],"AML.":[171],"complete":[175],"HD":[180,370],"GO":[182,256,283,340],"groups":[183,224,244],"90.9%,":[185],"89.5%":[186],"100%,":[188,212],"respectively":[189,201,213],"(p":[190,202,214],"=":[191,203,215,230],"0.57).":[192],"EFS":[193,346],"2-years":[195,207,219],"was":[196,208,220],"43.9%,":[197],"36.7%,":[198],"66.7%,":[200,228],"0.85).":[204],"RFS":[205],"53.0%,":[209],"39.0%,":[210],"0.18).":[216],"similar":[221,241,328,352],"all":[223,243,330],"(58.9%,":[225],"56.9%,":[226],"p":[229],"0.92).":[231],"rate":[233,318],"duration":[235,246],"cytopenias":[237,250],"after":[238],"among":[242,329],"(median":[245],"29":[247],"days),":[248],"however":[249,349,397],"more":[252],"common":[253],"group":[257,284],"following":[258],"consolidation.":[259],"major":[263,362,383],"bleeding,":[264,363],"admission":[265],"to":[266],"intensive":[268],"care":[269],"unit":[270],"(ICU),":[271],"new":[273],"onset":[274],"cardiomyopathy":[275],"(EF":[276],"50%)":[278],"(major":[285],"bleeding:":[286],"0%":[287],"5.3%":[290],"33.3%":[293,304,314],"GO;":[295,306],"ICU":[296,364],"admission:":[297],"12.1%":[298,308],"21.1%":[301],"cardiomyopathy:":[307],"26.3%":[311],"GO).":[316],"infection,":[320],"liver":[321],"dysfunction,":[322],"acute":[324],"renal":[325],"injury":[326],"groups.":[331],"No":[332],"developed":[334],"veno-occlusive":[335],"disease.":[336],"Conclusions:":[337],"receiving":[339,369],"trend":[343,373],"toward":[344,374],"improved":[345],"expense":[356],"cytopenias,":[361],"admission,":[365],"cardiotoxicity.":[367],"worse":[375],"than":[377],"those":[378],"who":[379],"SD.":[381],"A":[382],"limitation":[384],"our":[386],"study":[387],"small":[390],"sample":[391],"size":[392],"single":[394],"institution":[395],"experience,":[396],"multi-institutional":[398],"ongoing":[401],"further":[403],"investigation.[Table:":[404],"see":[405],"text]":[406]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2022-06-13T00:00:00"}